Synergistic treatment of ST-segment elevation myocardial infarction with pharmacoinvasive recanalization

Journal of the American College of Cardiology

Volumn 42, Issue 4, 2003, Pages 646-651

  Dauerman, Harold L ^a   Sobel, Burton E ^a,b  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ADENOSINE RECEPTOR BLOCKING AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; LOW MOLECULAR WEIGHT HEPARIN; STREPTOKINASE; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLEEDING; CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; FIBRINOLYTIC THERAPY; HEART DEATH; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; PRIORITY JOURNAL; RECANALIZATION; SKILL; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

EID: 0043233236     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00762-9     Document Type: Review

References (50)

1. Maroko PR, Kjekshus JK, Sobel BE, et al. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 1971;43:67-82.
2. Bergmann SR, Lerch RA, Fox KA, et al. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med 1982;73:573-81.
3. Collen D, Topol EJ, Tiefenbrunn AJ, et al. Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. Circulation 1984;70:1012-7.
4. Van de WF, Ludbrook PA, Bergmann SR, et al. Coronary thrombolysis with tissue-type plasminogen activator in patients with evolving myocardial infarction. N Engl J Med 1984;310:609-13.
5. Verstraete M, Bernard R, Bory M, et al. Randomised trial of intravenous recombinant tissue-type plasminogen activator versus intravenous streptokinase in acute myocardial infarction: report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator. Lancet 1985;1:842-7.
6. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-402.
7. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349-60.
8. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343:311-22.
9. Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
10. Dauerman HL, Lessard D, Yarzebski J, Furman MI, Gore JM, Goldberg RJ. Ten-year trends in the incidence, treatment, and outcome of Q-wave myocardial infarction. Am J Cardiol 2000;86:730-5.
11. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Christiansen CL, Gurwitz JH. Effectiveness of thrombolytic therapy for acute myocardial infarction in the elderly: cause for concern in the old-old. Arch Intern Med 2002;162:561-8.
12. Thiemann DR. Primary angioplasty for elderly patients with myocardial infarction: theory, practice and possibilities. J Am Coll Cardiol 2002;39:1729-32.
13. Berger AK, Radford MJ, Wang Y, Krumholz HM. Thrombolytic therapy in older patients. J Am Coll Cardiol 2000;36:366-74.
14. de Boer MJ, Ottervanger JP, van't Hof AW, Hoorntje JC, Suryapranata H, Zijlstra F. Reperfusion therapy in elderly patients with acute myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002;39:1723-8.
15. Dauerman HL, Goldberg RJ, White K, et al. Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002;90:838-42.
16. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial: the TIMI 14 investigators. Circulation 1999;99:2720-32.
17. Sobel BE. Conjunctive therapy for thrombolysis. Coron Artery Dis 1992;3:987-9.
18. Anderson JL, Karagounis LA, Becker LC, Sorensen SG, Menlove RL. TIMI perfusion grade 3 but not grade 2 results in improved outcome after thrombolysis for myocardial infarction: ventriculographic, enzymatic, and electrocardiographic evidence from the TEAM-3 study. Circulation 1993;87:1829-39.
19. Lenderink T, Simoons ML, Van Es GA, Van de WF, Verstraete M, Arnold AE. Benefit of thrombolytic therapy is sustained throughout five years and is related to TIMI perfusion grade 3 but not grade 2 flow at discharge: the European Cooperative study group. Circulation 1995;92:1110-6.
20. O'Neill W, Timmis GC, Bourdillon PD, et al. A prospective randomized clinical trial of intracoronary streptokinase versus coronary angioplasty for acute myocardial infarction. N Engl J Med 1986;314:812-8.
21. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction study group. N Engl J Med 1993;328:673-9.
22. Ryan TJ, Ryan TJ, Jr., Jacobs AK. Primary PTCA versus thrombolytic therapy: an evidence-based summary. Am Heart J 1999;138:S96-104.
23. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1997;336:1621-8.
24. Tiefenbrunn AJ, Chandra NC, French WJ, Gore JM, Rogers WJ. Clinical experience with primary percutaneous transluminal coronary angioplasty compared with alteplase (recombinant tissue-type plasminogen activator) in patients with acute myocardial infarction: a report from the Second National Registry of Myocardial Infarction (NRMI- 2). J Am Coll Cardiol 1998;31:1240-5.
25. Dauerman HL, Pinto DS, Ho KK, et al. Outcome of patients with acute myocardial infarction who are ineligible for primary angioplasty trials. Cathet Cardiovasc Intervent 2000;49:237-43.
26. Magid DJ, Calonge BN, Rumsfeld JS, et al. Relation between hospital primary angioplasty volume and mortality for patients with acute MI treated with primary angioplasty vs thrombolytic therapy. JAMA 2000;284:3131-8.
27. Berger PB, Ellis SG, Holmes DR, Jr., et al. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. Circulation 1999;100:14-20.
28. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA 2000;283:2941-7.
29. Anderson HR. The DANAMI-2 Study: DANish trial in Acute Myocardial Infarction. Paper presented at the Late Breaking Clinical Trials Session of the American College of Cardiology. March 20, 2002, Atlanta, Georgia.
30. Gibson CM. Time is myocardium and time is outcomes. Circulation 2001;104:2632-4.
31. Van de WF, Baim DS. Reperfusion for ST-segment elevation myocardial infarction: an overview of current treatment options. Circulation 2002;105:2813-6.
32. Weaver WD, Simes RJ, Betriu A, et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA 1997;278:2093-8.
33. Caputo RP, Ho KK, Stoler RC, et al. Effect of continuous quality improvement analysis on the delivery of primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1997;79:1159-64.
34. Angeja BG, Gibson CM, Chin R, et al. Predictors of door-to-balloon delay in primary angioplasty. Am J Cardiol 2002;89:1156-61.
35. Rogers WJ, Baim DS, Gore JM, et al. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator: results of the Thrombolysis In Myocardial Infarction (TIMI) phase II-A trial. Circulation 1990;81:1457-76.
36. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis In Myocardial Infarction (TIMI) phase II trial. N Engl J Med 1989;320:618-27.
37. Topol EJ, Califf RM, George BS, et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med 1987;317:581-8.
38. Simoons ML, Arnold AE, Betriu A, et al. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty. Lancet 1988;1:197-203.
39. Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO-4 pilot) trial. J Am Coll Cardiol 2000;36:1489-96.
40. Ross AM, Coyne KS, Reiner JS, et al. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol 1999;34:1954-62.
41. Dauerman HL, Prpic R, Andreou C, Popma JJ. Resolution of coronary thrombus with rescue stenting. Am J Cardiol 2000;85:1244-7.
42. Schweiger MJ, Cannon CP, Murphy SA, et al. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol 2001;88:831-6.
43. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 2001;104:636-41.
44. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
45. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.
46. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905-14.
47. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001;358:605-13.
48. Gurwitz JH, Goldberg RJ, Chen Z, Gore JM, Alpert JS. Recent trends in hospital mortality of acute myocardial infarction - the Worcester Heart Attack study. Have improvements been realized for all age groups? Arch Intern Med 1994;154:2202-8.
49. Angeja BG, Gunda M, Murphy SA, et al. TIMI myocardial perfusion grade and ST segment resolution: association with infarct size as assessed by single photon emission computed tomography imaging. Circulation 2002;105:282-5.
50. Baim DS, Wahr D, George B, et al. Randomized trial of a distal embolic protection device during percutaneous intervention of saphenous vein aorto-coronary bypass grafts. Circulation 2002;105:1285-90.